NYKODE THERAPEUTICS ASA (NYKD.OL) Fundamental Analysis & Valuation

OSL:NYKD • NO0010714785

Current stock price

3.135 NOK
-0.03 (-0.95%)
Last:

This NYKD.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NYKD.OL Profitability Analysis

1.1 Basic Checks

  • NYKD had negative earnings in the past year.
  • NYKD had a negative operating cash flow in the past year.
  • In the past 5 years NYKD always reported negative net income.
  • In the past 5 years NYKD reported 4 times negative operating cash flow.
NYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFNYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • The Return On Assets of NYKD (-12.25%) is comparable to the rest of the industry.
  • NYKD's Return On Equity of -13.37% is fine compared to the rest of the industry. NYKD outperforms 63.10% of its industry peers.
Industry RankSector Rank
ROA -12.25%
ROE -13.37%
ROIC N/A
ROA(3y)-18.14%
ROA(5y)-15.45%
ROE(3y)-20.8%
ROE(5y)-18.89%
ROIC(3y)N/A
ROIC(5y)N/A
NYKD.OL Yearly ROA, ROE, ROICNYKD.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NYKD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYKD.OL Yearly Profit, Operating, Gross MarginsNYKD.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NYKD.OL Health Analysis

2.1 Basic Checks

  • NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NYKD has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NYKD has been increased compared to 5 years ago.
  • NYKD has a worse debt/assets ratio than last year.
NYKD.OL Yearly Shares OutstandingNYKD.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
NYKD.OL Yearly Total Debt VS Total AssetsNYKD.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • NYKD has an Altman-Z score of 7.50. This indicates that NYKD is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.50, NYKD is doing good in the industry, outperforming 77.38% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that NYKD is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.01, NYKD is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 7.5
ROIC/WACCN/A
WACC8.54%
NYKD.OL Yearly LT Debt VS Equity VS FCFNYKD.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 10.00 indicates that NYKD has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 10.00, NYKD belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
  • A Quick Ratio of 10.00 indicates that NYKD has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 10.00, NYKD belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10
Quick Ratio 10
NYKD.OL Yearly Current Assets VS Current LiabilitesNYKD.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NYKD.OL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 68.75% over the past year.
  • NYKD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)68.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • NYKD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -25.25% yearly.
  • The Revenue is expected to grow by 377.69% on average over the next years. This is a very strong growth
EPS Next Y-114.29%
EPS Next 2Y6.9%
EPS Next 3Y-209.09%
EPS Next 5Y-25.25%
Revenue Next Year-100%
Revenue Next 2Y318.33%
Revenue Next 3Y60.5%
Revenue Next 5Y377.69%

3.3 Evolution

NYKD.OL Yearly Revenue VS EstimatesNYKD.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
NYKD.OL Yearly EPS VS EstimatesNYKD.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. NYKD.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NYKD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYKD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYKD.OL Price Earnings VS Forward Price EarningsNYKD.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYKD.OL Per share dataNYKD.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as NYKD's earnings are expected to decrease with -209.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.9%
EPS Next 3Y-209.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. NYKD.OL Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 31.60%, NYKD is a good candidate for dividend investing.
  • NYKD's Dividend Yield is rather good when compared to the industry average which is at 0.63. NYKD pays more dividend than 100.00% of the companies in the same industry.
  • NYKD's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 31.6%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • NYKD has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-263.67%
EPS Next 2Y6.9%
EPS Next 3Y-209.09%
NYKD.OL Yearly Income VS Free CF VS DividendNYKD.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

NYKD.OL Fundamentals: All Metrics, Ratios and Statistics

NYKODE THERAPEUTICS ASA

OSL:NYKD (4/17/2026, 7:00:00 PM)

3.135

-0.03 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-27
Inst Owners12.54%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap1.02B
Revenue(TTM)N/A
Net Income(TTM)-12.24M
Analysts82.86
Price Target4.59 (46.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 31.6%
Yearly Dividend0.92
Dividend Growth(5Y)N/A
DP-263.67%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)104.55%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0
BVpS2.62
TBVpS2.62
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -12.25%
ROE -13.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.14%
ROA(5y)-15.45%
ROE(3y)-20.8%
ROE(5y)-18.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.86%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10
Quick Ratio 10
Altman-Z 7.5
F-Score2
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)31.55%
Cap/Depr(5y)72.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.5%
EPS Next Y-114.29%
EPS Next 2Y6.9%
EPS Next 3Y-209.09%
EPS Next 5Y-25.25%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y318.33%
Revenue Next 3Y60.5%
Revenue Next 5Y377.69%
EBIT growth 1Y40.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.51%
EBIT Next 3Y-82.63%
EBIT Next 5Y102.93%
FCF growth 1Y42.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3YN/A
OCF growth 5YN/A

NYKODE THERAPEUTICS ASA / NYKD.OL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL.


What is the valuation status of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to NYKODE THERAPEUTICS ASA (NYKD.OL). This can be considered as Overvalued.


How profitable is NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

NYKODE THERAPEUTICS ASA (NYKD.OL) has a profitability rating of 1 / 10.


How sustainable is the dividend of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

The dividend rating of NYKODE THERAPEUTICS ASA (NYKD.OL) is 5 / 10 and the dividend payout ratio is -263.67%.